nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.12.2013 | Original Article

Reduced cardiac ¹²³I-metaiodobenzylguanidine uptake in patients with spinocerebellar ataxia type 2: a comparative study with Parkinson’s disease

verfasst von: Anna De Rosa, Sabina Pappatà, Teresa Pellegrino, Maria Fulvia De Leva, Gennaro Maddaluno, Giovanni Fiumara, Raffaella Carotenuto, Mario Petretta, Alessandro Filla, Giuseppe De Michele, Alberto Cuocolo

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 12/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Spinocerebellar ataxia type 2 (SCA2) is an autosomal dominant neurodegenerative disorder characterized by cerebellar ataxia, supranuclear ophthalmoplegia, and peripheral neuropathy. Autonomic nervous system dysfunction is often present. This study evaluated the cardiac sympathetic function in patients with SCA2 using ¹²³I-metaiodobenzylguanidine (MIBG) in comparison with patients with Parkinson’s disease (PD) and control subjects.

Methods

Nine patients with SCA2, nine patients with PD, and nine control subjects underwent ¹²³I-MIBG imaging studies from which early and late heart-to-mediastinum (H/M) ratios and myocardial washout rates were calculated.

Results

Early (F = 12.3, p < 0.0001) and late (F = 16.8, p < 0.0001) H/M ratios were significantly different among groups. In controls, early and late H/M ratios (2.2 ± 0.12 and 2.1 ± 0.20) were significantly higher than in patients with SCA2 (1.9 ± 0.23 and 1.8 ± 0.20, both p < 0.05) and with patients with PD (1.7 ± 0.29 and 1.4 ± 0.35, both p < 0.001). There was also a significant difference in washout rates among groups (F = 11.7, p < 0.0001). In controls the washout rate (19.9 ± 9.6 %) was significantly lower (p < 0.005) than in patients with PD (51.0 ± 23.7 %), but not different from that in SCA2 patients (19.5 ± 9.4 %). In SCA2 patients, in a multivariable linear regression analysis only the Scale for the Assessment and Rating of Ataxia score was independently associated with early H/M ratio (β = −0.12, p < 0.05).

Conclusion

¹²³I-MIBG myocardial scintigraphy demonstrated an impairment of cardiac sympathetic function in patients with SCA2, which was less marked than in PD patients. These results suggest that ¹²³I-MIBG cardiac imaging could become a useful tool for analysing the pathophysiology of SCA2.

Taki J, Yoshita M, Yamada M, Tonami N. Significance of 123I-MIBG scintigraphy as a pathophysiological indicator in the assessment of Parkinson’s disease and related disorders: it can be a specific marker for Lewy body disease. Ann Nucl Med. 2004;18:453–61.PubMedCrossRef

Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson’s disease. Brain. 1999;122:1437–48.PubMedCrossRef

Wakabayashi K, Tanji K, Mori F, Takahashi H. The Lewy body in Parkinson’s disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates. Neuropathology. 2007;27:494–506.PubMedCrossRef

Wolters EC. Non-motor extranigral signs and symptoms in Parkinson’s disease. Parkinsonism Relat Disord. 2009;15:S6–12.PubMedCrossRef

Oka H, Toyoda C, Yogo M, Mochio S. Reduced cardiac 123I-MIBG uptake reflects cardiac sympathetic dysfunction in de novo Parkinson’s disease. J Neural Transm. 2011;118:1323–7.PubMedCrossRef

Treglia G, Cason E, Stefanelli A, Cocciolillo F, Di Giuda D, Fagioli G, et al. MIBG scintigraphy in differential diagnosis of Parkinsonism: a meta-analysis. Clin Auton Res. 2012;22:43–55.PubMedCrossRef

Magaña JJ, Velázquez-Pérez L, Cisneros B. Spinocerebellar ataxia type 2: clinical presentation, molecular mechanisms, and therapeutic perspectives. Mol Neurobiol. 2013;47:90–104.PubMedCrossRef

Durr A. Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond. Lancet Neurol. 2010;9:885–94.PubMedCrossRef

De Joanna G, De Rosa A, Salvatore E, Castaldo I, De Luca N, Izzo R, et al. Autonomic nervous system abnormalities in spinocerebellar ataxia. J Neurol Sci. 2008;275:60–3.PubMedCrossRef

10.

Yomono HS, Kurisaki H, Hebisawa A, Sakiyama Y, Saito Y, Murayama S. Autopsy case of SCA2 with Parkinsonian phenotype. Rinsho Shinkeigaku. 2010;50:156–62.PubMedCrossRef

11.

Rascol O, Schelosky L. 123I-metaiodobenzylguanidine scintigraphy in Parkinson’s disease and related disorders. Mov Disord. 2009;24:S732–41.PubMedCrossRef

12.

Schmitz-Hübsch T, du Montcel ST, Baliko L, Berciano J, Boesch S, Depondt C, et al. Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology. 2006;66:1717–20.PubMedCrossRef

13.

Yeh TH, Lu CS, Chou YH, Chong CC, Wu T, Han NH, et al. Autonomic dysfunction in Machado-Joseph disease. Arch Neurol. 2005;62:630–6.PubMedCrossRef

14.

Fahn S, Elton RL; Members of the UPDRS Development Committee. The Unified Parkinson’s disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, editors. Recent developments in Parkinson’s disease, Vol. 2. Florham Park: Macmillan Healthcare Information; 1987. p. 153–63. 293–304.

15.

Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17:427–42.PubMedCrossRef

16.

Flotats A, Carrió I, Agostini D, Le Guludec D, Marcassa C, Schäfers M, et al.; EANM Cardiovascular Committee; European Council of Nuclear Cardiology. Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology. Eur J Nucl Med Mol Imaging. 2010;37:1802–12.PubMedCrossRef

17.

Dürr A, Smadja D, Cancel G, Lezin A, Stevanin G, Mikol J, et al. Autosomal dominant cerebellar ataxia type I in Martinique (French West Indies). Clinical and neuropathological analysis of 53 patients from three unrelated SCA2 families. Brain. 1995;118:157–81.CrossRef

18.

Gierga K, Bürk K, Bauer M, Orozco Diaz G, Auburger G, Schultz C, et al. Involvement of the cranial nerves and their nuclei in spinocerebellar ataxia type 2 (SCA2). Acta Neuropathol. 2005;109:617–31.PubMedCrossRef

19.

Kazuta T, Hayashi M, Shimizu T, Iwasaki A, Nakamura S, Hirai S. Autonomic dysfunction in Machado-Joseph disease assessed by iodine123-labeled metaiodobenzylguanidine myocardial scintigraphy. Clin Auton Res. 2000;10:111–5.PubMedCrossRef

20.

Pellegrino T, Petretta M, De Luca S, Paolillo S, Boemio A, Carotenuto R, et al. Observer reproducibility of results from a low-dose (123)I-metaiodobenzylguanidine cardiac imaging protocol in patients with heart failure. Eur J Nucl Med Mol Imaging. 2013. doi:10.1007/s00259-013-2461-4.

21.

Kline RC, Swanson DP, Wieland DM, Thrall JH, Gross MD, Pitt B, et al. Myocardial imaging in man with I-123 meta-iodobenzylguanidine. J Nucl Med. 1981;22:129–32.PubMed

22.

Sisson JC, Shapiro B, Meyers L, Mallette S, Mangner TJ, Wieland DM, et al. Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man. J Nucl Med. 1987;28:1625–36.PubMed

23.

Estorch M, Carrió I, Berná L, López-Pousa J, Torres G. Myocardial iodine-labeled metaiodobenzylguanidine 123 uptake relates to age. J Nucl Cardiol. 1995;2:126–32.PubMed

24.

Ji SY, Travin MI. Radionuclide imaging of cardiac autonomic innervation. J Nucl Cardiol. 2010;17:655–66.PubMedCrossRef

25.

Netravathi M, Sathyaprabha TN, Jayalaxmi K, Datta P, Nirmala M, Pal PK. A comparative study of cardiac dysautonomia in autosomal dominant spinocerebellar ataxias and idiopathic sporadic ataxias. Acta Neurol Scand. 2009;120:204–9.PubMedCrossRef

26.

Takao M, Aoyama M, Ishikawa K, Sakiyama Y, Yomono H, Saito Y, et al. Spinocerebellar ataxia type 2 is associated with Parkinsonism and Lewy body pathology. BMJ Case Rep. 2011;2011:bcr0120113685.PubMedCrossRef

27.

Varrone A, Salvatore E, De Michele G, Barone P, Sansone V, Pellecchia MT, et al. Reduced striatal [123I]FP-CIT binding in SCA2 patients without parkinsonism. Ann Neurol. 2004;553:426–30.CrossRef

28.

Estrada R, Galarraga J, Orozco G, Nodarse A, Auburger G. Spinocerebellar ataxia 2 (SCA2): morphometric analyses in 11 autopsies. Acta Neuropathol. 1999;97:306–10.PubMedCrossRef

29.

Filla A, De Michele G, Banfi S, Santoro L, Perretti A, Cavalcanti F, et al. Has spinocerebellar ataxia type 2 a distinct phenotype? Genetic and clinical study of an Italian family. Neurology. 1995;45:793–6.PubMedCrossRef

30.

van de Warrenburg BP, Notermans NC, Schelhaas HJ, van Alfen N, Sinke RJ, Knoers NV, et al. Peripheral nerve involvement in spinocerebellar ataxias. Arch Neurol. 2004;61:257–61.PubMedCrossRef

31.

Perretti A, Santoro L, Lanzillo B, Filla A, De Michele G, Barbieri F, et al. Autosomal dominant cerebellar ataxia type I: multimodal electrophysiological study and comparison between SCA1 and SCA2 patients. J Neurol Sci. 1996;142:45–53.PubMedCrossRef

Titel: Reduced cardiac 123I-metaiodobenzylguanidine uptake in patients with spinocerebellar ataxia type 2: a comparative study with Parkinson’s disease
verfasst von: Anna De Rosa
Sabina Pappatà
Teresa Pellegrino
Maria Fulvia De Leva
Gennaro Maddaluno
Giovanni Fiumara
Raffaella Carotenuto
Mario Petretta
Alessandro Filla
Giuseppe De Michele
Alberto Cuocolo
Publikationsdatum: 01.12.2013
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 12/2013
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-013-2524-6

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2013

Area under the cumulative SUV-volume histogram is not a viable metric of intratumoral metabolic heterogeneity: further comments

Pathology-based validation of FDG PET segmentation tools for volume assessment of lymph node metastases from head and neck cancer

Nuclear medicine 2013: from status quo to status go

Total lesion glycolysis by 18F-FDG PET/CT is a reliable predictor of prognosis in soft-tissue sarcoma

Combined 18F-fluoride and 18F-FDG PET/CT: a response based on actual data from prospective studies

Rapid blood clearance and lack of long-term renal toxicity of 177Lu-DOTATATE enables shortening of renoprotective amino acid infusion